## **Supporting Information**

## Baschant et al. 10.1073/pnas.1105857108

## **SI Materials and Methods**

**Mice**. BALB/c mice (Charles River Laboratories) and  $GR^{dim}$  (1),  $GR^{LysMCre}$  (2), and  $GR^{LckCre}$  (3) were back-crossed for at least four generations to the BALB/c background.  $GR^{CD11cCre}$  and  $GR^{CD19Cre}$  mice were generated by crossing to CD11cCre transgenic (4) and CD19Cre mice (5), respectively, and were back-crossed for at least four generations to the C57BL/6 background.  $GR^{dim}$  mice were also crossed for 12 generations to the DBA/1 background. IL-17A<sup>-/-</sup> (C57BL/6) and IFN- $\gamma^{-/-}$  (C57BL/6) mice were supplied by Yoichiro Iwakura (Tokyo, Japan) and the Jackson Laboratory, respectively. The mice were kept under specific pathogen-free conditions.

Antigen-Induced Arthritis. In brief, mice were immunized with 100  $\mu$ g methylated BSA (mBSA; Sigma-Aldrich) emulgated 1:1 with complete Freund's adjuvant (Sigma-Aldrich) supplemented with 1 mg/mL *Mycobacterium tuberculosis* (Difco) and simultaneously treated i.p. with 5 × 10<sup>8</sup> heat-inactivated *Bordtella pertussis* (Chiron-Behring) at days 21 and 14 before arthritis induction. Arthritis was induced by an intraarticular injection of 100  $\mu$ g mBSA into the right knee joint cavity (6). This was followed by i.v. treatment with 1.25 mg/kg Micromethason (Novosom AG) or PBS at 4, 24, and 48 h. Knee joint swelling was determined using an Oditest caliper (Kroeplin) and expressed relative to the knee diameter at day 0 (before arthritis induction).

**Glucose-6-Phosphate Isomerase-Induced Arthritis.** Glucose-6-phosphate isomerase-induced arthritis (G6PI-IA) was established as described elsewhere (7) using 6- to 10-wk-old GR<sup>dim</sup> mice (DBA/1 background) and monitored for 30 d. A score of 0 indicated no clinical signs of arthritis, 1 slight swelling and redness, 2 strong swelling and redness, and 3 massive swelling and redness. Dexamethasone (Dex; 1 mg/kg; Sigma-Aldrich) or PBS was applied daily i.p. starting from day 9 (onset of the disease) until day 15.

**Histology.** Knee joints were removed at day 1 after AIA induction, fixed in phosphate-buffered 4% formalin for 24 h, and subsequently decalcified with 15% EDTA, dehydrated, and embedded in paraffin, and 6- $\mu$ m sections were stained with H&E. Histological scoring was performed blindly according to Tolk and Földi's grading of joint inflammation from 0 to 3 regarding (*i*) cellular infiltration, (*ii*) fibrin exudation into the joint space, (*iii*) lining cell layer, and (*iv*) synovitis of subintimal connective tissue, and the average was calculated (8).

**Serum Analysis.** Eight hours after AIA induction, several cytokines (IFN- $\gamma$ , IL-6, IL-17, and TNF- $\alpha$ ) were analyzed in serum with a cytometric bead array (BD Biosciences) and subsequent flow cytometry according to the manufacturer's instructions.

Blood was taken from the animals 24 h after AIA induction. Protein levels of IL-6, IL-17, and IFN- $\gamma$  were measured by a sandwich ELISA (R&D Systems) according to the manufacturer's instructions.

- Reichardt HM, et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531–541.
- Tuckermann JP, et al. (2007) Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest 117:1381–1390.
- Baumann S, et al. (2005) Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. *Blood* 106:617–625.
- Caton ML, Smith-Raska MR, Reizis B (2007) Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J Exp Med 204:1653–1664.

Lymph Node Cell Analysis. Cells from draining lymph nodes (inguinal and popliteal) were isolated 24 h after AIA induction, and 1 mL was cultured ( $7.5 \times 10^6$  cells/mL; 48-well plates; 37 °C, 5% CO<sub>2</sub>) in RPMI medium (PAA Laboratories) containing 10% FCS, 1% penicillin/streptomycin, and 50 µM 2-mercapto-ethanol (Gibco) with either 25 µg mBSA or with 5 ng/mL 4 $\alpha$ -phorbol 12-myristate 13-acetate and 1 µg/mL ionomycin. After 2 h, brefeldin A (eBioscience) was added, and after a further 4 h, cells were harvested for flow cytometry. Cells were subsequently stained with anti–CD4-PECy7 (L3T3), anti–CD154-APC, anti–IL17A-FITC (eBio17B7), anti–IFN- $\gamma$ -PE (XMG1.1), and anti–TNF $\alpha$ -eF405 (MP6-XT22).

**Proliferation and Apoptosis Measurements.** BrdU (2 mg) was injected i.p. 4 h after arthritis induction in glucocorticoid (GC)and PBS-treated mice. Twenty hours after BrdU application, inguinal and popliteal lymph nodes were removed and isolated cells stained for flow cytometry [anti–CD4-PECy7, anti–CD3-APC (17A2)], fixed and permeabilized (BD Cytofix/Cytoperm Buffer), and subsequently stained with anti-BrdU (FITC) antibody (BD Biosciences). Apoptosis was determined by incubating lymph node cells with FITC-labeled annexin V and 50  $\mu$ g/mL propidium iodide (Molecular Probes). FACS analysis was performed using a FACSCanto (BD Biosciences), and the data were processed with FlowJo software (version 8.7; Tree Star).

**T<sub>H</sub>17 in Vitro Differentiation.** Naïve CD4<sup>+</sup>TCRβ<sup>+</sup>CD62L<sup>high</sup>C-D44<sup>low</sup> cells were purified from spleens and lymph nodes of BALB/c mice by flow cytometry sorting (FACSAria; BD Biosciences) after staining with anti–CD4-PECy7, anti–TCRβ-APC (H57-597), anti–CD62L-FITC (MEL-14), and anti–CD44-PE (IM7) antibodies. Purified T cells were activated by plate-bound anti-CD3 and anti-CD28 antibodies (5 µg/mL of each) and cultured in the presence of 10 µg/mL anti–IL-4 (11B11), 10 µg/mL anti–IFN-γ (XMG.1) (eBioscience), IL-6 (PeproTech), TGF-β (PeproTech), IL-1β (ImmunoTools), and TNF-α (ImmunoTools). After 7 d, cells were restimulated with plate-bound anti-CD28 antibodies (5 µg/mL of each) for 6 h, in the presence of brefeldin A for the final 4 h, and treated with 1 µM Dex. Subsequently, cells were analyzed by FACS as described above.


**Quantitative Real-Time PCR for Recombination Efficiencies.** Leukocytes of GR<sup>CD11cCre</sup>, GR<sup>CD19Cre</sup>, and GR<sup>LckCre</sup> mice were purified from different hematopoietic organs using flow cytometry sorting (FACSAria; BD Biosciences) after staining with indicated cell surface markers. DNA was isolated from the purified cells, and quantitative real-time PCR amplifying the GR<sup>flox</sup> allele was performed with an iCycler (Bio-Rad) using a Sensi-Mix DNA Kit containing SYBR Green (Invitrogen). Primer information can be supplied on request.

Rickert RC, Roes J, Rajewsky K (1997) B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 25:1317–1318.

Brackertz D, Mitchell GF, Mackay IR (1977) Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20:841–850.

Schubert D, Maier B, Morawietz L, Krenn V, Kamradt T (2004) Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol 172:4503–4509.

<sup>8.</sup> Berry EC, Grundmann E, Kirsten W (1982) Bone and Joint Disease (Current Topics in Pathology) (Springer, New York).



20 0

120

100 -80 -60 -40 -20 -0 **DP** 

% of GR<sup>flox</sup> allele

Ε

TCRB+

CD19+

Spleen

CD4+ CD8+

DN

CD11c+

**GR**LckCre

B220+

CD11b+

Bone marrow


GR1<sup>hi</sup> CD11b+ TCRB+ CD19+ CD11c+

GR1<sup>hi</sup>


| в |                                  |                     |                      |  |
|---|----------------------------------|---------------------|----------------------|--|
| D | Cell type                        | Surface<br>markers  | Recombi-<br>nation % |  |
|   | Macrophages<br>(Spleen)          | F4/80+/<br>MHCII+   | 65.0                 |  |
|   | DC (Spleen)                      | CD11c+/<br>MHCII+   | 95.3                 |  |
|   | T cells (Spleen)                 | TCR <sub>\$</sub> + | 52.0                 |  |
|   | Neutrophile<br>granuloc. (Blood) | GR1hi               | 62.0                 |  |
|   | T cells (Blood)                  | CD4+                | 76.5                 |  |
|   | T cells (Blood)                  | CD8+                | 67.3                 |  |
|   | B cells (Blood)                  | CD19+               | 0.0                  |  |

| D | Cell type         | Surface<br>markers  | Recombi-<br>nation % |
|---|-------------------|---------------------|----------------------|
|   | T cells (Spleen)  | TCR <sub>\$</sub> + | 0.0                  |
|   | B cells (Spleen)  | CD19+               | 96.6                 |
|   | DC (Spleen)       | CD11c+              | 1.7                  |
|   | B cells (BM)      | B220+               | 79.2                 |
|   | Macrophages (BM)  | CD11b+              | 0.0                  |
|   | Neutrophile       | GR1hi               | 0.0                  |
|   | granulocytes (BM) |                     |                      |

| Cell Type                        | Surface<br>markers | Recombi-<br>nation % |
|----------------------------------|--------------------|----------------------|
| DP (Thymus)                      | CD4+CD8+           | 99.7                 |
| DN (Thymus)                      | CD4-CD8-           | 16.3                 |
| T cells (Thymus)                 | CD4+               | 99.1                 |
| T cells (Thymus)                 | CD8+               | 98.0                 |
| Neutrophile<br>granulocytes (BM) | GR1hi              | 19.8                 |
| Macrophages (BM)                 | CD11b+             | 0.0                  |
| T cells (Spleen)                 | TCR <sup>®+</sup>  | 99.0                 |
| B cells (Spleen)                 | CD19+              | 3.6                  |
| DC (Spleen)                      | CD11c+             | 1.0                  |




**Fig. S1.** Recombination efficiency of the GR<sup>flox</sup> allele in different Cre lines. (*A*, *C*, and *E*) Abundance of the GR<sup>flox</sup> allele in leukocytes of (*A*) GR<sup>CD11cCre</sup>, (*C*) GR<sup>CD19Cre</sup>, and (*E*) GR<sup>LckCre</sup> mice determined by quantitative real-time PCR. Cells were sorted by flow cytometry with antibodies against indicated cell surface markers. DP, double-positive (CD4<sup>+</sup>/CD8<sup>+</sup>) cells; DN, double-negative (CD4<sup>-</sup>CD8<sup>-</sup>) cells. (*B*, *D*, and *F*) Summarized recombination efficiencies (%) of the GR<sup>flox</sup> allele into the deleted GR allele for (*B*) GR<sup>CD11cCre</sup>, (*D*) GR<sup>CD19Cre</sup>, and (*F*) GR<sup>LckCre</sup> mice, calculated from values in *A*, *C*, and *E*, respectively. (*G*) Determination of the GR<sup>flox</sup> and the GR<sup>dim</sup> allele in T cells of GR<sup>dim/flox;LckCre</sup> mice. Thymocytes and T cells from the indicated organs were sorted by flow cytometry with indicated cell surface markers and the GR<sup>dim</sup>, the GR<sup>loxP</sup>, and the deleted GR<sup>del</sup> allele amplified by PCR.




**Fig. 52.** mBSA-specific IgG levels and G6PI-specific IgG levels in serum of arthritic mice are not changed with GC treatment. (*A*) mBSA-specific IgG levels were determined at day 3 after AIA induction in serum of PBS- and Dex-treated mice by ELISA (n = 5). Pooled sera from AIA mice were used as the relative reference for antibodies specific to mBSA. (*B*) G6PI-specific IgG levels were determined at day 12 after G6PI-IA induction in serum of PBS- and Dex-treated mice by ELISA (n = 3). The highest serum dilution in which anti-G6PI antibodies were still detectable is shown on the y axis.


AS PNAS




**Fig. S3.** Cell compartments of  $GR^{flox}$  and  $GR^{LckCre}$  mice have comparable T cell numbers. (*A*) Thymocytes of  $GR^{LckCre}$  mice and their respective littermate control mice  $GR^{flox}$  were analyzed by flow cytometry with antibodies against surface expression of CD4 and CD8 (*Upper*). The number of CD4<sup>+</sup>, CD8<sup>+</sup>, double-positive (DP) CD4<sup>+</sup>CD8<sup>+</sup>, and double-negative (DN) CD4<sup>-</sup>CD8<sup>-</sup> cells was determined by calculating the frequencies of the respective cells in the total number of cells (*Lower*; n = 3). (*B*) Splenic T cells of  $GR^{LckCre}$  and  $GR^{flox}$  mice were analyzed by flow cytometry as described in *A*. The number of CD4<sup>+</sup> and CD8<sup>+</sup> cells was determined by calculating the frequencies of the respective cells in the total number of cells (n = 3).




**Fig. S4.** GC-mediated suppression of AIA and IL-17 in mice with a fully established disease requires the GR in T cells. (*A*) Treatment scheme of AIA induction and Dex application. Mice were immunized s.c. twice at day -21 and -14 with 100 µg mBSA before arthritis induction by intraarticular injection of 100 µg mBSA at day 0. At day 1 (and day 2) after arthritis induction when the disease is already established, mice were treated with either 1.25 mg/kg Dex or PBS i.v. (*B*) GR<sup>LckCre</sup> mice and their respective littermate control (GR<sup>flox</sup>) mice were subjected to AIA and treated with PBS or Dex as described in *A*. Knee joint swelling was measured mechanically at indicated time points. (*C*) The serum IL-17 level was measured by ELISA in GR<sup>flox</sup> and GR<sup>LckCre</sup> mice before arthritis induction (day 0) and at day 2. Animals were treated as described in *A*. In *B* and *C*, *n* = 5–6; \**P* < 0.05; \*\**P* < 0.01; n.s., not significant.




**Fig. S5.** Serum cytokine levels in PBS- and Dex-treated arthritic WT and  $GR^{dim}$  mice 8 h after AIA induction. IL-6 (A) and IFN- $\gamma$  (B) were determined in WT and GR<sup>dim</sup> animals treated as described in Fig. 1A 8 h after AIA induction. In A and B, n = 5-6; \*P < 0.05, \*\*P < 0.01; n.s., not significant.




**Fig. S6.** G6PI-IA in WT and GR<sup>dim</sup> mice. (A) WT and GR<sup>dim</sup> mice were immunized with G6PI and treated from day 9 until day 15 with PBS or 1 mg/kg Dex. Paw swelling was scored from day 0 to day 30 at indicated time points. (B) Severity of G6PI-IA at day 12. In both panels, n = 5; \*P < 0.05; \*\*P < 0.01; n.s., not significant.



**Fig. 57.** Apoptosis and proliferation of total lymph node cells from PBS- and Dex-treated WT mice at day 1 after AIA induction. (A) Apoptosis was determined by annexin V-positive cells by flow cytometry analysis of CD4<sup>+</sup> cells (n = 5). (B) Proliferation was measured by determination of BrdU incorporation after 24 h. Single cell suspensions of draining lymph nodes were analyzed by flow cytometry for BrdU-positive cells (n = 5).



**Fig. S8.** Gating strategy and FACS analysis of activated CD154<sup>+</sup> cells in the draining lymph nodes of mice. (A) Cells from draining lymph nodes were isolated at day 1 after AIA induction and restimulated for 6 h with 25  $\mu$ g mBSA. Cells were subsequently stained for CD4 and intracellularly for CD154, IFN- $\gamma$ , TNF- $\alpha$ , and IL-17. Cells were gated for singlet cells, followed by a lymphocyte gate. T helper cells were identified through CD4, mBSA-specific T cells through CD154 expression. Cytokine analysis was performed by creating gates for IFN- $\gamma$ , TNF- $\alpha$ , and IL-17. (B) Cells of the draining lymph nodes derived from arthritic PBS- and Dex-treated WT and GR<sup>dim</sup> mice were restimulated ex vivo for 6 h with mBSA and further analyzed for CD154 expression by intracellular flow cytometry analysis. The frequencies of total for CD154 expression are shown (n = 18-24). (C) Intracellular flow cytometry analysis for TNF- $\alpha$ , IFN- $\gamma$ , and IL-17 in restimulated draining lymph node cells with the gating strategy described in A. The bars show the frequencies of the respective cytokines within the CD154<sup>+</sup> cells (n = 18-24).



**Fig. S9.** Regulatory T cells in the draining lymph nodes from PBS- and Dex-treated WT mice at day 1 after AIA induction and influence of GCs on IL-17 production in T<sub>H</sub>17 cells. (*A*) FACS analysis of restimulated (6 h with 25  $\mu$ g mBSA) lymph node cells stained for CD25, CD4, and FoxP3. A representative plot of CD25<sup>+</sup>FoxP3<sup>+</sup> cells of the CD4<sup>+</sup> gate is shown. Numbers indicate the mean of frequencies. (*B*) Total number of regulatory T cells in draining lymph nodes of mice (*n* = 5; \**P* < 0.05). (*C*) Naïve T cells from WT and GR<sup>dim</sup> mice were sorted for CD4<sup>+</sup>TCRβ<sup>+</sup>CD62L<sup>high</sup>CD44<sup>low</sup> cells and differentiated for 7 d under T<sub>H</sub>17-promoting conditions. After 7 d, T<sub>H</sub>17 cells were restimulated for 6 h and treated with a pharmacological dose (10<sup>-6</sup> M) of Dex. Representative FACS images with mean values of frequencies are shown. The graph shows the mean and SD of IL-17 frequencies (*n* = 3; \**P* < 0.05).